Management and Board
BOL Pharma’s leadership team is comprised of industry professionals with a diverse set of relevant expertise, relationships and experience. They have more than 10 years of growing / cultivation experience in Israel as well as a wealth of knowledge and experience from previous roles at global pharmaceutical companies.
BOL’s scientific advisory board is comprised of individuals with extensive industry expertise and relationships in strategically valuable fields. Many hold positions at leading universities, medical institutions and research centres around the world, and are instrumental in helping us develop partnerships of choice with medical establishments and the foremost experts.
Hagai has dedicated his career to cultivating and growing export agriculture produce utilizing advanced agriculture technologies and groundbreaking Agro-methodologies. He is the founder and Chairman of the Israeli Licensed Medical Cannabis Growers Association.
He has established multiple relationship and collaborations with local academic institutions developing significantly improved agro-growth methods, plant genetics techniques, chemical stabilization protocols, and many other developments all aimed at maximizing medicinal value in botanical produce.
Government licensed grower of medical Cannabis since 2008, Hagai has established an advanced research facility and labs for the cultivation of unique Cannabis genetic strands and production of Botanical Cannabinoids for the Pharma, Medical Cosmetics and Food Supplements industries.
Dr. Tamir Gedo
Dr. Tamir Gedo serves as the CEO of BOL Pharma, one of Israel’s pioneers driving the worldwide medical cannabis industry. In this capacity, he draws upon 25 years as a marketing and business strategy expert serving in academic, government, and industry functions.
Dr. Gedo possesses extensive expertise in international marketing, branding, entrepreneurship, and business strategy. As a Senior Manager, Dr. Gedo has contributed to a wide range of branding, strategic planning, and market penetration activities of major companies in a variety of industries. As a consultant, Dr. Gedo provided services to companies in the medical, food, nutritional supplements, and pharma industries. In parallel to his business and consulting practice, Dr. Tamir has served as the head of the marketing department and other faculty positions of several colleges in Israel and was a guest lecturer in the Department of Business Administration of Shanghai University.
Over the years, he has taught undergraduate and graduate level courses in global marketing, business strategy, innovation, and entrepreneurship. Dr. Gedo received his Ph.D. in Behavioral Economics from Manchester Business School (UK) and an MBA from Ben Gurion University (Israel). He completed a B.Sc. in Molecular Biology at Bar Ilan University (Israel).
25 years of senior leadership experience in finance and operations with high growth public technology and medical devices companies leading revenue growth and profitability, creating significant value for shareholders.
He has played an instrumental role in successful IPOs, M&A, spin-offs, and fund raising into private and public companies, with extensive experience in capital markets (Nasdaq, TASE, AIM) and investor relations. Mr. Goldman served from 2012 until recently as CFO of Syneron Medical Ltd, a global leader in the aesthetic medical devices, was traded on Nasdaq until acquired by APAX. Previously, served as CFO of: Retalix, Ltd., a leading global provider of software and services to high volume, high complexity retailers that was dual-listed on Nasdaq and the TASE until it was acquired by NCR Corporation, AxisMobile, taking it public in London on the AIM stock exchange, VocalTec Communications Ltd., a pioneer in VoIP that was listed on Nasdaq and Motorola Semiconductor Israel (acquired by Freescale Semiconductor Inc.). Mr. Goldman began his career at PWC, holds a bachelor’s degree in Accounting and Economics from the University of Tel-Aviv and an Executive M.B.A. from Bradford University with distinction. He is a certified public accountant in Israel and member of the Steering Committee of the Israeli CFO Forum.
Sagi Ben Rimon
General Manager of BOL Israel
In a career spanning over 20 years, Sagi has held several leadership positions mainly in the pharma industry. Before joining BOL Pharma, he had completed 14 years with Teva Pharmaceuticals Ltd.
Where he held several positions of responsibility, including Vice-President, Operations Network strategic planning and Manager of the Kfar Saba Oral Solid Dosages plant, a 900 employee, $100M expense and over $1 Billion revenue pharmaceutical manufacturing plant. Before that Sagi has served as VP R&D and Manufacturing for Optonol, a company specializing in Ophthalmic implants.
Sagi holds an MBA in Business Management as well as a B.Sc in Mechanical engineering, both from the Ben Gurion University in Beer Sheba.
Avner has 20 years of experience of agriculture and agro-technology management. Avner has advanced within BOL undertaking leading positions for the past five years and has a proven track record of corporate executives in complex projects relating to medical cannabis growth, cultivation, and commercialization
Dr. Medy Wiener is our Chief Medical Officer and leads our Medical and Drug Development activities.
She is a multidisciplinary high-level executive
that brings more than two decades of experience in the global Pharma and Biotech field with a diverse skill and a proven track record in drug development, pharmacovigilance, medical affairs, business development and strategy. She served in various management positions in global Pharma companies – Chief Scientific Officer in Novartis Pharma, VP Corporate Strategy at Teva and lately as Head of BD and Medical Affairs at Allergan. Dr Wiener holds a Medical Doctor degree from Tel Aviv university and an MBA from the Interdisciplinary Center and was trained at Cardiff University in Pharmaceutical Medicine.
Prof. Itamar Raz
Advisory Board Member
Prof. Raz is a Professor of Internal Medicine at Hadassah University Hospital, and currently serves as the Head of the Israeli National Council of Diabetes and is the initiator and leader of the National Diabetes Prevention and Care Plan in Israel.
Additionally, Prof. Raz is President of D-Cure, a non-profit organization that promotes and funds scientific research in Israel for finding a cure and better treatments for diabetes. He previously served as president of the Israel Diabetes Association. Prof Raz has performed numerous animal and clinical studies in Diabetes and published them in peer reviewed journals. Prof Raz studied at the Hadassah Hebrew University Medical School in Jerusalem.
Prof. Simon Benita
Advisory Board Member
Prof. Simon Benita is the former Director of the Institute for Drug Research and the School of Pharmacy at The Hebrew University of Jerusalem, where he received his Ph.D. in Pharmacy.
His research is focused on polymeric nano and microparticulate and lipid-based drug delivery systems aimed at improving ocular bioavailability, dermal penetration and drug targeting. Prof. Benita formed and supervises a large research lab, has published numerous research articles and book chapters and has multiple patents and patent applications. Prof. Benita has served as a member of the Board of Pharmaceutical Sciences of the International Pharmacy Federation and Governor of the Controlled Release Society.
Prof. Ron Kohen
Advisory Board Member
Prof. Kohen is the former Head of Hebrew University’s School of Pharmacy and the Institute for Drug Research.
His research focuses on anti-oxidants and he studies specifically cannabinoids as antioxidants in biological systems; modulation of the skin defense mechanism against stress by cannabinoids, topical nano-delivery of cannabinoids (gold nano particles and microemulsion). He has authored numerous research articles and reviews proceedings, abstracts and book chapters.
Dr. Adi Aran
Advisory Board Member
Dr. Aran is the Head of the Pediatrics Neurology Department at Shaare Zedek Medical Center in Jerusalem. Dr. Aran has also focused efforts on understanding the therapeutic effects of CBD-based medical cannabis in neurocognitive disorders, including ASD.
Dr Aran initiated studies exploring the effects of medical cannabis on epilepsy and ASD and is the lead researcher of the world’s first clinical study on the efficacy & safety of cannabis for ASD. Dr Aran serves as a consultant to the Ministry of Health for medical cannabis indications and use in children and spends much time educating physicians and lay audiences on the subject. He trained at the Hebrew University-Hadassah Medical School, Jerusalem, Israel and the Biochemistry Department of Psychiatry, Stanford University.
Prof. Francisco Xavier Castellanos
Prof. Castellanos is a pioneer in the study of the structure and function of the brain in neurodevelopmental disorders such as Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder.
He is a professor in the Department of Child and Adolescent Psychiatry, Hassenfeld Children’s Hospital at NYU Langone, and Professor of Radiology and Neuroscience at the NYU Langone Health School of Medicine.
Dr. Rachel Grossman
Dr. Grossman is Vice-President of the Neurosurgery Department of Tel Aviv Sourasky Medical Centre is a leading investigator at the Brain Cancer Research Lab at the Sourasky Medical Center.
She has vast clinical and basic research experience in Glioblastoma and has published multiple articles in peer-reviewed journals. She has trained at the Sheba Medical Center, completed a Postdoctoral Fellowship. at the Lawrence National Laboratory, University of California, Berkeley, and completed a Neurosurgical Fellowship at Johns Hopkins University School of Medicine, Baltimore.
Prof. Howard Amital
Prof. Amital has produced hundreds of peer-reviewed publications in various fields of autoimmunity research. Mr. Amital is the Head of the Department of Medicine ‘B’ and The Zabludowicz Center for Autoimmune Diseases at the Sheba Medical Center.
Mr. Amital’s papers mainly focus on autoimmunity research primarily in new avenues for the roles of vitamin D, use of biological therapy, pain and comorbidities of fibromyalgia and epidemiological studies based on Health Maintenance Organization databases.
Dr. Itay Goor-Aryeh
Dr. Goor-Aryeh is the Director of the Pain Clinic at the Sheba Medical Center in Tel Hashomer. He serves as an executive board member of the Israeli Pain Association and a member of the Executive Board of the Israeli Medical Cannabis Association
and has played a key part in defining the regulations and indications of medical cannabis use in Israel. He has extensive clinical experience with Cannabis and has conducted and published numerous studies in the Cannabis area. He trained in Anesthesia and Pain Management at Beth Israel Hospital, Harvard Medical School.
Dr. Silviu Brill
Dr. Brill is a Director at the Institute of Pain Medicine, Department of Anesthesiology and Intensive Care at the Tel Aviv Sourasky Medical Centre.
Dr. Brill is also an executive member of the Israeli Pain Association and serves as the General Secretary of the executive board of the pain division of the Israeli Anesthesia Association. He also served as Co-Chair of the European Pain Federation task force on Cannabinoids and as Honorary Secretary, EFIC (European Federation of IASP Chapters). He runs one of the leading pain management clinics in Israel and has extensive clinical and scientific experience in the cannabis field.
Dr. Dror Robinson
Dr. Robinson serves as the Head of the Foot and Ankle Department and Head of the Orthopedic Research Unit at Hasharon Hospital at the Rabin Medical Center.
He previously served as Chairman of the Orthopedics Department at Hasharon Hospital and as Head of the Orthopedic Oncology Unit at Assaf Harofe Hospital. Dr. Robinson is a senior lecturer in the Department of Orthopedic Surgery at Tel Aviv University’s Sackler School of Medicine. His research concentrates on the repair of cartilage injuries using autologous cells, either cultured chondrocytes or mesenchymal cells. He has conducted numerous animal and human trials and published many articles in peer-reviewed journals.
Prof. Ido Wolf
Prof. Wolf serves as the Head of the Oncology Division at the Tel Aviv Sourasky Medical Center and is an Associate Professor at the Tel Aviv University.
He serves as a member of the National Committee for the Prevention and Treatment of Malignant Diseases, of the Israel Ministry of Health, and the Israeli National Committee for Clinical Trials. He has received numerous awards for his scientific work covering both basic research and clinical aspects of solid tumors. Professor Wolf completed his Postdoctoral Fellowship at the Division of Hematology Oncology, Cedar-Sinai Medical Center, UCLA School of Medicine.
Prof. Oren Shibolet
Prof. Shibolet is the Head of the Liver Unit in the Department of Gastroenterology and Liver Disease at the Tel Aviv Sourasky Medical Center.
He is a principal investigator with research grants from the Israeli Academy of Science, Israel Association of Cancer Research and the Bi-national Science Foundation and a reviewer for multiple journals and funding agencies. He Trained at the Hadassah Medical Center in Internal Medicine and Gastroenterology and Hepatology and did his Research Fellowship at Massachusetts General in Boston.
Prof. David Soriano
Prof. Soriano is a world known expert in obstetrics, gynecology, and infertility and is the Founder and the Director of the first and the biggest Israeli multi-disciplinary Centre for Endometriosis at the Sheba Medical Centre.
Prof. Soriano is the author of numerous articles on gynecological and endometriosis surgery. He was previously President of the Israel Society of Gynaecological Endoscopy. Prof. Soriano is a Professor of Obstetrics and Gynaecology at the Sackler School of Medicine at Tel Aviv University. He is a member of the European Society of Human Reproduction and Embryology and takes part in defining the treatment guidelines on Endometriosis.
Prof. Avraham Domb
Prof. Domb is the Head of the School of Pharmacy at the Hebrew University of Jerusalem and is a Professor for Medicinal Chemistry and Biopolymers.
He was also previously the R&D Manager at Nova Pharm. Co. His research focuses on biodegradable polymers, pharmaceutical formulations, drug delivery systems and medicinal chemistry, and has resulted in several products, including: Gliadel, Superfloc, Deximmune, Bioprotect, Inspace, Cunker Cover, OraMiost and MAZE. Prof. Domb earned his Bachelor’s degrees in Chemistry, Pharmaceutics and Law Studies, as well as a PhD degree in Chemistry from The Hebrew University of Jerusalem. He did his postdoctoral training at MIT and Harvard University.
Prof. Amnon Hoffman
Prof. Hoffman serves as the Chairman of the Division of Clinical Pharmacy and the Head of the Drug Delivery Systems Lab at the Hebrew University of Jerusalem.
He has over 15 years of experience in the field of pharmacokinetics and pharmacodynamics, specializing in the biological aspects of drug delivery systems. He has conducted many PK and PD studies have authored multiple book chapters and hold several patents. Specifically, he published a study on “Affecting Intestinal First Pass Metabolism Processes of Orally Administered Drugs by Pharmaceutical Methodology: The Cannabinoids Paradigm”.
Mr. Malka is an expert in clinical trials and data management, with over 20 years of work experience in the life science industry.
He founded Bioforum Applied Knowledge Center, an international faculty of life-sciences, and Bioforum the Data Masters, a global data-focused CRO, and IMP, clinical supply chain manager. Mr. Malka is a member of several life sciences and clinical trial associations and is an active advocate in helping break down barriers to help further advance these medical industries in Israel.